#1
|
|||
|
|||
Äèàãíîñòèðîâàëè ãëàóêîìó, íàñêîëüêî àäåêâàòíî ëå÷åíèå?
Ïðîñüáà îöåíèòü íàçíà÷åíèå âðà÷à.
1. áåòàêñîëîë 4% ïî 2, 3 ðàçà â äåíü 2. ïèëîêàðïèí ïî 2, 1 ðàç íà íî÷ü 3. êàâèíòîí ïî 1 øò, 3 ðàçà ïîñëå åäû 4. ôëîêñàäåêñ ïî 2, 3 ðàçà ïîñëå åäû. íå ìíîãî ëè äëÿ æåíùèíû 48 ëåò. |
#2
|
|||
|
|||
Äëÿ î÷åíêè îäíèõ íàçíà÷åíèé ìàëîâàòî, íóæíû äàííûå îáñëåäîâàíèÿ: ÂÃÄ, òîíîãðàôèÿ, Ê×ÑÌ, çàêëþ÷åíèå ïî ïåðèìåòðèè.
|
#3
|
|||
|
|||
ê÷ñì äëÿ ÷åãî?
|
#4
|
|||
|
|||
Ôëîêñàäåêñ íå ïðåïàðàò äëÿ ëå÷åíèÿ ãëàóêîìû. Âàì åãî íà êàêîé ñðîê íàçíà÷èëè? Êðîìå ãëàóêîìû åùå êàêîé-òî äèàãíîç ïîñòàâèëè?
|
#5
|
|||
|
|||
Ñòðàííûé âîïðîñ äëÿ ÷åãî Ê×ÑÌ...äëÿ îïðåäåëåíèÿ ñòåïåíè ÃÎÍ, êàê è ïåðèìåòðèÿ, â ïðî÷åì. Ìû æå ãëàóêîìó íå òîëüêî ïî óðîâíþ ÂÃÄ êîíòðîëèðóåì â äèíàìèêå. Ïî÷åìó-òî ïðî íåéðîïðîòåêòèâíîå ëå÷åíèå ïðè ãëàóêîìå ìàëî êòî ïîìíèò. À æàëü.
|
#6
|
||||
|
||||
Öèòàòà:
Ê×ÑÌ íå ÿâëÿåòñÿ êðèòåðèåì îïðåäåëåíèÿ ñòåïåíè ÃÎÍ, à ñëåäîâàòåëüíî íå èñïîëüçóåòñÿ â äèàãíîñòèêå ãëàóêîìû, à òåì áîëåå â å¸ äèñïàíñåðèçàöèè. Èíîãäà Ê×ÑÌ ìîæåò áûòü èñïîëüçîâàí ëèøü äëÿ êîíñòàòàöèè ôàêòà àòðîôèè çðèòåëüíîãî íåðâà ïðè ðàçëè÷íûõ çàáîëåâàíèÿõ. Íåò. Åù¸ ïî ïåðèìåòðèè, êîìïüþòåðíîé åñòåññíî.. Æåëàòåëüíî humfrey. À îòêóäà òåðìèí "íåéðîïðîòåêòèâíîå ëå÷åíèå ãëàóêîìû"? È â ÷¸ì îíî çàêëþ÷àåòñÿ? |
#7
|
|||
|
|||
èìåííî,ñ...
|
#8
|
|||
|
|||
òåðìèí íåéðîïðîòåêöèÿ â òîì ÷èñëå è ïðè ãëàóêîìå èçâåñòåí è äîñòàòî÷íî ïîëíî ïðåäñòàâëåí â ðàáîòàõ îòå÷åñòâåííûõ àâòîðîâ (öèòèðîâàòü íåò ñìûñëà), òàêæå âñòðå÷àåòñÿ è çà ðóáåæîì (íå ìåíåå ÷àñòî)......çàêëþ÷àåòñÿ îí â òîì ÷òîáû îáîðâàòü ÂÃÄ-íåçàâèñìûå ìåõàíèçìû ðàçâèòèÿ ÃÎÍ....òàê íàïðèìåð:1. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage.
Fang JH, Wang XH, Xu ZR, Jiang FG. 2.Nihon Ganka Gakkai Zasshi. 2011 Mar;115(3):213-36; discussion 237. [Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma]. âûãëÿäÿò îïòèìèñòè÷íî, îäíàêî ñëåäóÿ ïèðàìèäå äîêàçàòåëüíîñòè ñóùåñòâóåò ñèñòåì îáçîð êîòîðûé ÿâëÿÿñü íàèâûñøåé åå ñòóïåíüþ è äîëæåí áûòü ïðèíÿò íà âåðó: Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006539. Neuroprotection for treatment of glaucoma in adults. Sena DF, Ramchand K, Lindsley K. ....îäíèì èç íàèáîëåå "ïåðñïåêòèâíûõ" ñ÷èòàëñÿ ìåìàíòèí, îäíàêî: 4.Acta Ophthalmol. 2009 Jun;87(4):450-4. Epub 2009 Jan 9. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned ....ïî ìíåíèþ íåêîòîðûõ àâòîðîâ ëó÷øàÿ íåéðîïðîòåêöèÿ ýòî ñíèæåíèå ÂÃÄ)))))...õîòÿ òåìà èíòåðåñíàÿ è âîçìîæíà äèñêóññèÿ |